Related Experiment Video
Updated: Mar 10, 2026
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
Juan José Castón1,2, Álvaro De la Torre3, Isabel Ruiz-Camps4
1Clinical Unit of Infectious Diseases, Hospital Universitario Reina Sofía-Instituto Maimónides de Investigación Biomédica (IMIBIC), Córdoba, Spain.
Abstract:
Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.
Insights
Ceftolozane-tazobactam salvage therapy showed promise for severe multidrug-resistant Pseudomonas aeruginosa infections. Despite high rates of septic shock, this treatment led to a 58.3% microbiological cure rate in patients with difficult-to-treat infections.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Multidrug-resistant Pseudomonas aeruginosa (MDRPA) infections pose significant therapeutic challenges.
- Severe MDRPA infections, including pneumonia, often require salvage treatment options.
Purpose of the Study:
- To evaluate the efficacy and outcomes of ceftolozane-tazobactam as salvage therapy in patients with severe MDRPA infections.
- To assess the clinical response, mortality, and microbiological cure rates in this patient cohort.
Main Methods:
- Retrospective analysis of 12 patients with severe MDRPA infections treated with ceftolozane-tazobactam.
- Patients received salvage therapy after initial inappropriate empirical or suboptimal targeted treatment.
- Outcomes including septic shock, mortality, and microbiological cure were recorded.
Main Results:
- 83.3% of patients (10/12) experienced septic shock.
- The 30-day mortality rate was 25% (3/12).
- Microbiological cure was achieved in 58.3% of patients (7/12).
Conclusions:
- Ceftolozane-tazobactam demonstrated potential as a salvage therapy for severe MDRPA infections.
- Despite high rates of critical illness, a significant proportion of patients achieved microbiological cure.
- Further research is warranted to optimize treatment strategies for MDRPA infections.
More Related Videos
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...